These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 21453265)
1. Part I: targeted particles for cancer immunotherapy. Hamdy S; Haddadi A; Ghotbi Z; Hung RW; Lavasanifar A Curr Drug Deliv; 2011 May; 8(3):261-73. PubMed ID: 21453265 [TBL] [Abstract][Full Text] [Related]
2. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Klippstein R; Pozo D Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824 [TBL] [Abstract][Full Text] [Related]
3. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Hamdy S; Haddadi A; Hung RW; Lavasanifar A Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cells and their role in cancer immunotherapy. Jalili A Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012 [TBL] [Abstract][Full Text] [Related]
5. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens. Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834 [TBL] [Abstract][Full Text] [Related]
6. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205 [TBL] [Abstract][Full Text] [Related]
7. Acquisition and Presentation of Tumor Antigens by Dendritic Cells. Bonaccorsi I; Campana S; Morandi B; Ferlazzo G Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848 [TBL] [Abstract][Full Text] [Related]
8. Dendritic Cells and Cancer Immunity. Gardner A; Ruffell B Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569 [TBL] [Abstract][Full Text] [Related]
9. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells as vectors for immunotherapy of cancer. Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Van Nuffel AM; Corthals J; Neyns B; Heirman C; Thielemans K; Bonehill A Methods Mol Biol; 2010; 629():405-52. PubMed ID: 20387165 [TBL] [Abstract][Full Text] [Related]
12. Part II: targeted particles for imaging of anticancer immune responses. Hung RW; Hamdy S; Haddadi A; Ghotbi Z; Lavasanifar A Curr Drug Deliv; 2011 May; 8(3):274-81. PubMed ID: 21291375 [TBL] [Abstract][Full Text] [Related]
13. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918 [TBL] [Abstract][Full Text] [Related]
14. Tumor cell lysates as immunogenic sources for cancer vaccine design. González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929 [TBL] [Abstract][Full Text] [Related]
15. Harnessing Dendritic Cells for Poly (D,L-lactide- Koerner J; Horvath D; Groettrup M Front Immunol; 2019; 10():707. PubMed ID: 31024545 [TBL] [Abstract][Full Text] [Related]
16. Advances in dendritic cell-based vaccine of cancer. Zhang X; Gordon JR; Xiang J Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664 [TBL] [Abstract][Full Text] [Related]
17. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based cancer immunotherapies. Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202 [TBL] [Abstract][Full Text] [Related]